
Zipradon20 mg
Drug International Ltd.
Ziprasidone is an atypical antipsychotic.
Ziprasidone is an atypical antipsychotic. Its FDA-approved and evidence-supported uses include:
Ziprasidone is occasionally used off-label, based on limited evidence, for adjunctive management of other psychiatric conditions; such use should be individualized by a physician and is not FDA-approved.
Ziprasidone is not approved for the treatment of dementia-related psychosis in elderly patients (see Precautions and Warnings for the boxed warning on increased mortality in this population).
Ziprasidone dosing must be individualized by a physician based on indication, response, and tolerability. Oral Ziprasidone must always be taken with food (a meal of at least 500 calories), as absorption is significantly reduced on an empty stomach.
| Indication | Adult dosage |
|---|---|
| Schizophrenia | Initial: 20 mg twice daily with food. May be adjusted at intervals of not less than 2 days, up to 80 mg twice daily, based on response and tolerability. Maintenance: lowest effective dose. |
| Bipolar I disorder, acute manic/mixed episode (monotherapy) | Day 1: 40 mg twice daily with food. Day 2: 60-80 mg twice daily. Subsequent days: adjust between 40-80 mg twice daily based on response. |
| Bipolar I disorder, maintenance (adjunct to lithium or valproate) | 40-80 mg twice daily with food, continuing the dose used during the acute treatment phase. |
| Acute agitation in schizophrenia (intramuscular) | 10 mg by intramuscular injection every 2 hours, or 20 mg every 4 hours, up to a maximum of 40 mg per day, for no more than 3 consecutive days; switch to oral therapy as soon as clinically appropriate. |
Renal impairment: No dosage adjustment is required for oral Ziprasidone. The intramuscular formulation contains a renally cleared cyclodextrin excipient and should be used with caution in renal impairment.
Hepatic impairment: Lower doses should be considered, as clearance may be reduced; use with caution.
A missed dose should be taken as soon as remembered unless it is nearly time for the next dose, in which case it should be skipped; doses should never be doubled. Ziprasidone should not be stopped abruptly without consulting a physician.
Common: Somnolence/sedation, headache, nausea, constipation, dizziness, akathisia (restlessness), extrapyramidal symptoms (tremor, rigidity), dyspepsia, and respiratory tract infection are reported with Ziprasidone.
Less common but clinically important: Orthostatic hypotension, weight gain, and metabolic changes such as elevated blood glucose or lipids (see Precautions and Warnings).
Rare but serious: QT-interval prolongation and torsades de pointes, neuroleptic malignant syndrome, tardive dyskinesia, seizures, priapism, and allergic reactions including rash and, rarely, severe skin reactions.
Patients taking Ziprasidone should seek prompt medical attention for palpitations, fainting, high fever with muscle rigidity, uncontrolled muscle movements, or signs of an allergic reaction.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.